Trials
1 active
1 in total
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Influenza
- Main trialPhase 3
- “The purpose of this study is to evaluate humoral immunogenicity after 2 doses of mRNA-1018-H5, and to evaluate the safety and reactogenicity of mRNA-1018-H5 in adults ≥18 years of age.”In the company’s words, NCT07496450 on ClinicalTrials.gov
Other drugs for Influenza
- Baloxavir MarboxilRoche · Phase 3
- BRC-201Boryung Biopharma Co., Ltd. · Phase 3
- Dipyrone monohydrateBrainfarma Industria Química e Farmacêutica S/A · Phase 3
- CD388Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Phase 3
- MRNA Seasonal Flu vaccineGSK · Phase 3
- GP681Jiangxi Qingfeng Pharmaceutical Co. Ltd. · Phase 3
Coming up1
- 28 Jan 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 28 Jan 2027 | A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026